|
|
 |
|
Viewing report
|
|
|
|
Anti-Obesity Drugs - Global Strategic Business Report
Global Industry Analysts, Inc., Feb 2009, Pages: 442
This report analyzes the worldwide markets for Anti-Obesity Drugs in Millions of US$. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2005 through 2015.
The report profiles 85 companies including many key and niche players worldwide such as Abbott Laboratories, Alizyme Plc, Amylin Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Sanofi-Aventis SA, SuperGen, Inc., Takeda Pharmaceutical Company Limited, and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Prescription Drugs - Global Strategic Business Report
Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report
Indian Bulk Drugs
Over-the-Counter (OTC) Pharmaceuticals and Drugs in Japan: A Strategic Reference, 2007
Infectious Diseases Drugs Markets
Respiratory Drugs - Global Strategic Business Report
Pen Injectors - Devices, Drugs & Disease Therapeutics
The 2009 Report on Botanical Drugs, Alkaloids Drugs, Naturally Occurring Vitamins, Drugs of Animal Origin, and Artificial Mixtures of Two or More Medical or Botanical Substances: World Market Segmentation by City
The 2009-2014 World Outlook for Botanical Drugs, Alkaloids Drugs, Naturally Occurring Vitamins, Drugs of Animal Origin, and Artificial Mixtures of Two or More Medical or Botanical Substances
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
Multiple Sclerosis Treatment Market: Opportunities for Oral Drugs
Emerging Blockbusters: 2009's Most Promising Drugs and the Future of the Blockbuster Model
|
|
|
|
